A Clinical Study of iEPC Intervent Subjects With Cerebral Hemorrhagic Stroke
A Safety and Efficacy Study of Human Peripheral Blood Derived Induced EPCs for Cerebral Hemorrhagic Stroke
調査の概要
詳細な説明
研究の種類
入学 (予想される)
段階
- 初期フェーズ 1
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Subjects ≥ 18 and ≤ 80 years of age
Subjects was confirmed cerebral hemorrhagic stroke, included at least one of risk factors(Hypertension, diabetes, coronary heart disease, high blood lipid), and Satisfied with one of the following conditions:
A. Significant stenosis (> 50%) of the intracranial and extracranial arteries or their branches due to atherosclerosis, or clinical or imaging manifestations of vascular blockage B. Head imaging (CT or MRI) : cerebral hemispheric infarct lesion diameter of > 1.5cm; Or there were more than 2 discontinuous lesions in the blood supply area of the same intracranial external artery.
C. Auxiliary examination: color ultrasonography, CTA, MRA or DSA of the blood vessels in the neck confirmed that the intracranial or extracranial stenosis was greater than or equal to 50%;
- Serum creatinine ≤ 1.5 mg/dl ; Serum ALT/AST)≤2.5×ULN;ALB≥25g/L;
- Serum creatinine≤ 176.8umol/L(2.0 mg/dl);
- Prothrombin time(PT)≤15s,International standardization rates(INR)<1.7;
- The glucose should be control between 2.8~22.2mmol/L(50~400mg/dl);
- Adult patients were willing to use reliable contraceptives (such as condoms) and not to donate sperm throughout the study period and within three months of discharge
- Subjects and the guardians able to undergo post-physical therapy/rehabilitation
Exclusion Criteria:
- Non-atherogenic cerebral infarction: cardiogenic embolization, small artery occlusion type IS, other exact etiology IS, and unknown etiology IS
- Combined with cerebral hemorrhage or previous intracranial external blood history, arteriovenous malformation and aneurysm history, or prone to hemorrhage (platelet count below 100 x 109/L)
- The vital signs of subjects are not stable
- Subjects with Class III/IV cardiovascular disability according to the New York Heart Association Classification
- At rest systolic pressure of 170mmHg or diastolic pressure of 105mmHg, or other indications of uncontrolled hypertension
- Subjects have one kinds of tumors within 5 years
- The subject was suffering from neurological or mental illness
- Subjects had congenital or acquired immune deficiencies, active tuberculosis and other active infections (e.g., pulmonary infection, urinary tract infection, skin infection)
- alcoholics
- Receipt of any investigational drug or device within 3 month
- Active hepatitis B (HBV DNA>1000copy/mL), hepatitis C or HIV infection
- Subjects who have other conditions that were not appropriate for the group determined by the researchers.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:EPC treatment group
|
Brain injection EPC
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Incidence of Treatment Emergent AE
時間枠:1 year
|
Defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment
|
1 year
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (予想される)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
EPC treatment groupの臨床試験
-
Allife Medical Science and Technology Co., Ltd.First Affiliated Hospital Xi'an Jiaotong University募集
-
Exciton Technologies Inc.完了
-
Washington State UniversityNational Institute on Drug Abuse (NIDA)完了
-
Shanghai 10th People's HospitalThe First Affiliated Hospital with Nanjing Medical Universityわからない
-
Reistone Biopharma Company Limited完了
-
Northern TherapeuticsUnity Health Toronto; Sir Mortimer B. Davis - Jewish General Hospital完了
-
Allife Medical Science and Technology Co., Ltd.まだ募集していません
-
Centre Hospitalier Universitaire de Nice終了しました